Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination

Clinical Cancer Research

Volumn 10, Issue 1 II, 2004, Pages

  Nicholson, Robert I ^a   Hutcheson, Iain R ^a   Knowlden, Janice M ^a   Jones, Helen E ^a   Harper, Maureen E ^a   Jordan, Nicola ^a   Hiscox, Steve E ^a   Barrow, Denise ^a   Gee, Julia M W ^a   Bissell, Mina ^b   Brown, Myles ^b   Ingle, James ^b   Green, Jeffrey ^b   Arteaga, Carlos ^b   Ellis, Matthew ^b   Santen, Richard ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Cardiff University ^*

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FULVESTRANT; GEFITINIB; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CELL STRAIN MCF 7; CONFERENCE PAPER; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; HORMONE RESISTANCE; HUMAN; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL DIVISION; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENDOCRINE GLANDS; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; GROWTH SUBSTANCES; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 9144251561     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-031206     Document Type: Conference Paper

References (103)

1. Nicholson, R. I., and Gee, J. M. Oestrogen and growth factor crosstalk and endocrine insensitivity and acquired resistance in breast cancer. Br. J. Cancer, 82: 501-513, 2000.
2. Nicholson, R. I., Hutcheson, I. R., Harper, M. E., Knowlden, J. M., Barrow, D., McClelland, R. A., Jones, H. E., Wakeling, A. E., and Gee, J. M. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr. Relat. Cancer, 8: 175-182, 2001.
3. Wakeling, A. E., Nicholson, R. I., and Gee, J. M. Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin. Cancer Res., 7 (Suppl.): 4350s-4355s; discussion 4411s-4412s, 2001.
4. Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Gorman, C. M., Parker, M. G., Sliwkowski, M. X., and Slamon, D. J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 10: 2435-2446, 1995.
5. Lupu, R., Cardillo, M., Cho, C., Harris, L., Hijazi, M., Perez, C., Rosenberg, K., Yang, D., and Tang, C. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res. Treat., 38: 57-66, 1996.
6. Tang, C. K., Perez, C., Grunt, T., Waibel, C., Cho, C., and Lupu, R. Involvement of heregulin-β2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res., 56: 3350-3358, 1996.
7. McClelland, R. A., Barrow, D., Madden, T. A., Dutkowski, C. M., Pamment, J., Knowlden, J. M., Gee, J. M., and Nicholson, R. I. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology, 142: 2776-2788, 2001.
8. Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M., Harper, M. E., Barrow, D., Wakeling, A. E., and Nicholson, R. I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 144: 1032-1044, 2003.
9. Guvakova, M. A., and Surmacz, E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp. Cell Res., 231: 149-162, 1997.
10. Stephen, R. L., Shaw, L. E., Larsen, C., Corcoran, D., and Darbre, P. D. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J. Biol. Chem., 276: 40080-40086, 2001.
11. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1993.
12. Liu, Y., el-Ashry, D., Chen, D., Ding, I. Y., and Kern, F. G. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res. Treat., 34: 97-117, 1995.
13. Kurokawa, H., Lenferink, A. E., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 60: 5887-5894, 2000.
14. Hutcheson, I. R., McClelland, R. A., Knowlden, J. M., Barrow, D., Wakeling, A. E., Gee, J. M. W., and Nicholson, R. I. Increased sensitivity of tamoxifen- and fulvestrant-resistant MCF-7 breast cancer cells to the growth inhibitory action of ZD1839 ("Iressa"). In: First International Symposium on Signal Transduction Modulators in Cancer Therapy Proceedings, Amsterdam, The Netherlands: NDDO Research Foundation. Vol. 1, p. 18. 2002.
15. Yarden, R. I., Wilson, M. A., and Chrysogelos, S. A. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J. Cell. Biochem., 81: 232-246, 2001.
16. DeFazio, A., Chiew, Y. E., McEvoy, M., Watts, C. K., and Sutherland, R. L. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth Differ., 8: 903-911, 1997.
17. van Agthoven, T., van Agthoven, T. L., Portengen, H., Foekens, J. A., and Dorssers, L. C. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res., 52: 5082-5088, 1992.
18. Miller, D. L., el-Ashry, D., Cheville, A. L., Liu, Y., McLeskey, S. W., and Kern, F. G. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ., 5: 1263-1274, 1994.
19. Vickers, P. J., Dickson, R. B., Shoemaker, R., and Cowan, K. H. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol. Endocrinol., 2: 886-892, 1988.
20. Long, B., McKibben, B. M., Lynch, M., and van den Berg, H. W. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance of oestrogen independence in the ZR-75-1 human breast cancer cell line. Br. J. Cancer, 65: 865-869, 1992.
21. van Agthoven, T., van Agthoven, T. L., Dekker, A., Foekens, J. A., and Dorssers, L. C. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol. Endocrinol., 8: 1474-1483, 1994.
22. van den Berg, H. W., Claffie, D., Boylan, M., McKillen, J., Lynch, M., and McKibben, B. Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br. J. Cancer, 73: 477-481, 1996.
23. Martin, L. A., Farmer, I., Johnston, S. R., Ali, S., Marshall, C. J., and Dowsett, M. Enhanced ERα ERBB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem., 278: 30458-30468, 2003.
24. Gee, J. M., Robertson, J. F., Ellis, I. O., and Nicholson, R. I. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer, 4: 247-254, 2001.
25. Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., and Greenberg, M. E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science (Wash. DC), 286: 1358-1362, 1999.
26. Gibson, S., Tu, S., Oyer, R., Anderson, S. M., and Johnson, G. L. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J. Biol. Chem., 274: 17612-17618, 1999.
27. Stambolic, V., Mak, T. W., and Woodgett, J. R. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene, 18: 6094-6103, 1999.
28. Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., and Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J. Biol. Chem., 276: 9817-9824, 2001.
29. Coutts, A. S., and Murphy, L. C. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res., 58: 4071-4074, 1998.
30. Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J. Biol. Chem., 276: 40888-40895, 2001.
31. Oh, A. S., Lorant, L. A., Holloway, J. N., Miller, D. L., Kern, F. G., and El-Ashry, D. Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol. Endocrinol., 15: 1344-1359, 2001.
32. Kurokawa, H., and Arteaga, C. L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin. Cancer Res., 9: 511S-515S, 2003.
33. Jeng, M. H., Yue, W., Eischeid, A., Wang, J. P., and Santen, R. J. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res. Treat., 62: 167-175, 2000.
34. Tonetti, D. A., Chisamore, M. J., Grdina, W., Schurz, H., and Jordan, V. C. Stable transfection of protein kinase C α cDNA in hormone-dependent breast cancer cell lines. Br. J. Cancer, 83: 782-791, 2000.
35. Hutcheson, I. R., Knowlden, J. M., Madden, T. A., Barrow, D., Gee, J. M. W., Wakeling, A. E., and Nicholson, R. I. Oestrogen receptor mediated modulation of the EGFR/MAPK pathway in tamoxifen resistant MCF-7 cells. Breast Cancer Res. Treat., 81: 81-93, 2003.
36. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science (Wash. DC), 270: 1491-1494, 1995.
37. Bunone, G., Briand, P. A., Miksicek, R. J., and Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J., 15: 2174-2183, 1996.
38. Ali, S., Metzger, D., Bornert, J. M., and Chambon, P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human estrogen receptor A/B region. EMBO J., 12: 1153-1160, 1993.
39. Britton, D., Hutcheson, I. R., Barrow, D., Gee, J. M. W., and Nicholson, R. I. Increased oestrogen receptor phosphorylation at serine 118 in tamoxifen resistant MCF-7 breast cancer cells. Biochem. Soc. Trans., 31: P114, 2002.
40. Chan, C. M., Martin, L. A., Johnston, S. R., Ali, S., and Dowsett, M. Molecular changes associated with the acquisition of estrogen hypersensitivity in MCF-7 breast cancer cells on long-term estrogen deprivation. J. Steroid Biochem. Mol. Biol., 81: 333-341, 2002.
41. Yee, D., and Lee, A. V. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J. Mammary Gland Biol. Neoplasia, 5: 107-115, 2000.
42. Hamelers, I. H., and Steenbergh, P. H. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr. Relat. Cancer, 10: 331-345, 2003.
43. Lee, A. V., Weng, C. N., Jackson, J. G., and Yee, D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J. Endocrinol., 152: 39-47, 1997.
44. Guvakova, M. A., and Surmacz, E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res., 57: 2606-2610, 1997.
45. Coppola, D., Ferber, A., Miura, M., Sell, C., D'Ambrosio, C., Rubin, R., and Baserga, R. A functional insulin-like growth factor 1 receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. Cell. Biol., 14: 4588-4595, 1994.
46. Gilmore, A. P., Valentijn, A. J., Wang, P., Ranger, A. M., Bundred, N., O'Hare, M. J., Wakeling, A., Korsmeyer, S. J., and Streuli, C. H. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem., 277: 27643-27650, 2002.
47. Roudabush, F. L., Pierce, K. L., Maudsley, S., Khan, K. D., and Luttrell, L. M. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J. Biol. Chem., 275: 22583-22589, 2000.
48. Wang, D., Patil, S., Li, W., Humphrey, L. E., Brattain, M. G., and Howell, G. M. Activation of the TGFα autocrine loop is downstream of IGF-1 receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene, 21: 2785-2796, 2002.
49. Gee, J. M. W., and Knowlden, J. M. Viewpoint: ADAM metalloproteases and EGFR signalling. Breast Cancer Res., 5: 223-224, 2003.
50. Balana, M. E., Labriola, L., Salatino, M., Movsichoff, F., Peters, G., Charreau, E. H., and Elizalde, P. V. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene, 20: 34-47, 2001.
51. Wiseman, L. R., Johnson, M. D., Wakeling, A. E., Lykkesfeldt, A. E., May, F. E., and Westley, B. R. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur. J. Cancer, 29A: 2256-2264, 1993.
52. Parisot, J. P., Hu, X. F., DeLuise, M., and Zalcberg, J. R. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br. J. Cancer, 79: 693-700, 1999.
53. Daly, R. J., Harris, W. H., Wang, D. Y., and Darbre, P. D. Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ., 2: 457-464, 1991.
54. Surmacz, E., and Burgaud, J. L. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin. Cancer Res., 1: 1429-1436, 1995.
55. Abdul-Wahab, K., Corcoran, D., Perachiotti, A., and Darbre, P. D. Overexpression of insulin-like growth factor II (IGFII) in ZR-75-1 human breast cancer cells: higher threshold levels of receptor (IGFIR) are required for a proliferative response than for effects on specific gene expression. Cell Prolif., 32: 271-287, 1999.
56. Hiscox, S., Wakeling, A. E., and Nicholson, R. I. Inhibition of the metastatic potential of tamoxifen-resistant breast cancer cells by gefitinib ("Iressa," AZ1839). Proc. Am. Assoc. Cancer Res., 44: 4863, 2003.
57. Atlas, E., Bojanowski, K., Mehmi, I., and Lupu, R. A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity. Oncogene, 22: 3441-3451, 2003.
58. Thompson, E. W., Brunner, N., Torri, J., Johnson, M. D., Boulay, V., Wright, A., Lippman, M. E., Steeg, P. S., and Clarke, R. The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin. Exp. Metastasis, 11: 15-26, 1993.
59. Wells, A. Tumor invasion: role of growth factor-induced cell motility. Adv. Cancer Res., 78: 31-101, 2000.
60. Barnes, C. J., Bagheri-Yarmand, R., Mandal, M., Yang, Z., Clayman, G. L., Hong, W. K., and Kumar, R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pakl pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol. Cancer Ther., 2: 345-351, 2003.
61. Ranson, M. ZD1839 (Iressa™): for more than just non-small cell lung cancer. Oncologist, 7: 16-24, 2002.
62. Sirotnak, F. M. Studies with ZD1839 in preclinical models. Semin. Oncol., 30 (Suppl. 1): 12-20, 2003.
63. Herbst, R. S. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin. Investig. Drugs, 11: 837-849, 2002.
64. Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J., and Gibson, K. H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res., 62: 5749-5754, 2002.
65. Nicholson, R. I., McClelland, R. A., Finlay, P., Eaton, C. L., Gullick, W. J., Dixon, A. R., et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki-67 immunostaining in breast cancer and hormone sensitivity. Eur. J. Cancer, 29A: 1018-1023, 1993.
66. Nicholson, R. I., McClelland, R. A., Gee, J. M., Manning, D. L., Cannon, P., Robertson, J. F., Ellis, I. O., and Blamey, R. W. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res. Treat., 29: 117-125, 1994.
67. Nicholson, R. I., McClelland, R. A., Gee, J. M., Manning, D. L., Cannon, P., Robertson, J. F., Ellis, I. O., and Blamey, R. W. Transforming growth factor-α and endocrine sensitivity in breast cancer. Cancer Res., 54: 1684-1689, 1994.
68. Nicholson, R. I., Gee, J. M., and Harper, M. E. EGFR and cancer prognosis. Eur. J. Cancer, 37: 9-15, 2001.
69. Klijn, J. G., Look, M. P., Portengen, H., Alexieva-Figusch, J., van Putten, W. L., and Foekens, J. A. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res. Treat., 29: 73-83, 1994.
70. Mueller, H., Flury, N., Eppenberger-Castori, S., Kueng, W., David, F., and Eppenberger, U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int. J. Cancer, 89: 384-388, 2000.
71. Adeyinka, A., Nui, Y., Cherlet, T., Snell, L., Watson, P. H., and Murphy, L. C. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin. Cancer Res., 8: 1747-1753, 2002.
72. Gee, J. M. W., Madden, T. A., Robertson, J. F. R., and Nicholson, R. I. Clinical response and resistance to SERMS. In: J. F. R. Robertson, R. I. Nicholson, and D. F. Hayes (eds.), Endocrine Therapy in Breast Cancer, pp. 155-190. London: Martin Dunitz Ltd., 2002.
73. Perez-Tenorio, G., and Stal, O. Southeast Sweden Breast Cancer Group: activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer, 86: 540-545, 2002.
74. Tonetti, D. A., Morrow, M., Kidwai, N., Gupta, A., and Badve, S. Elevated protein kinase C a expression may be predictive of tamoxifen treatment failure. Br. J. Cancer, 88: 1400-1402, 2003.
75. Robertson, J. F. R., Gutteridge, E., Cheung, K. L., Owers, R., Koehler, M., Hamilton, L., Gee, J., and Nicholson, R. I. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a Phase II study. Proc. Am. Soc. Clin. Oncol., 22: 7, 2003.
76. Ross, J. S., and Fletcher, J. A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist, 3: 237-252, 1998.
77. Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., and Miles, D. W. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer, 79: 1220-1226, 1999.
78. Mass, R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin. Oncol., 27 (Suppl. 11): 46-52, 2000.
79. Dowsett, M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer, 8: 191-195, 2001.
80. Dowsett, M., Harper-Wynne, C., Boeddinghaus, I., Salter, J., Hills, M., Dixon, M., Ebbs, S., Gui, G., Sacks, N., and Smith, I. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res., 61: 8452-8458, 2001b.
81. Lonn, U., Lonn, S., Ingelman-Sundberg, H., Nilsson, B., and Stenkvist, B. C-erb-b2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment. Int. J. Cancer, 69: 273-277, 1996.
82. Dowsett, M., Gutierrez, C., Mohsin, S., Schiff, R., Detre, S., Johnston, S., and Osborne, C. K. Molecular changes in tamoxifen-relapsed breast cancer: relationship between ER, HER2 and P38-MAP-kinase. Proc. Am. Soc. Clin. Oncol., 22: 3, 2003.
83. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., and Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol., 20: 719-726, 2002.
84. Witters, L. M., Kumar, R., Chinchilli, V. M., and Lipton, A. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res. Treat., 42: 1-5, 1997.
85. Witters, L., Engle, L., and Lipton, A. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol. Rep., 9: 1163-1166, 2002.
86. Railo, M. J., von Smitten, K., and Pekonen, F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur. J. Cancer, 30A: 307-311, 1994.
87. Peyrat, J. P., Bonneterre, J., Vennin, P. H., Jammes, H., Beuscart, R., Hecquet, B., Djiane, J., Lefebvre, J., and Demaille, A. Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors. J. Steroid Biochem. Mol. Biol., 37: 823-827, 1990.
88. Schnarr, B., Strunz, K., Ohsam, J., Benner, A., Wacker, J., and Mayer, D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int. J. Cancer, 89: 506-513, 2000.
89. Rocha, R. L., Hilsenbeck, S. G., Jackson, J. G., VanDenBerg, C. L., Weng, C., Lee, A. V., and Yee, D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin. Cancer Res., 3: 103-109, 1997.
90. Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., and Roth, R. A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem., 274: 21528-21532, 1999.
91. Turner, B. C., Haffty, B. G., Narayanan, L., Yuan, J., Havre, P. A., Gumbs, A. A., Kaplan, L., Burgaud, J. L., Carter, D., Baserga, R., and Glazer, P. M. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res., 57: 3079-3083, 1997.
92. Albanell, J., and Baselga, J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J. Natl. Cancer Inst. (Bethesda), 93: 1830-1832, 2001.
93. Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., and Pollak, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. (Bethesda), 93: 1852-1857, 2001,
94. Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascon, P., Gonzalez, S., Guillen, V., Sauleda, S., Averbuch, S., and Rojo, F. Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., 22: 191, 2003.
95. Scotlandi, K., Maini, C., Manara, M. C., Benini, S., Serra, M., Cerisano, V., Strammiello, R., Baldini, N., Lollini, P. L., Nanni, P., Nicoletti, G., and Picci, P. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther., 9: 296-307, 2002.
96. Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., and Arteaga, C. L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counter-acts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene, 22: 2812-2822, 2003.
97. Clark, A. S., West, K., Streicher, S., and Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther., 1: 707-717, 2002.
98. Clark, A. S., West, K. A., Blumberg, P. M., and Dennis, P. A. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCδ promotes cellular survival and chemotherapeutic resistance. Cancer Res., 63: 780-786, 2003.
99. Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., Seelig, S., and Arteaga, C. L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res., 62: 4132-4141, 2002.
100. Camirand, A., Lu, Y., and Pollak, M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med. Sci. Monit., 8: BR521-BR526, 2002.
101. Gee, J. M. W., Harper, M. E., Hutcheson, I. R., Madden, T. A., Barrow, D. Knowlden, J. M., McClelland, R. A., Jordan, N., Wakeling, A. E., and Nicholson, R. I. ZD1839 ("Iressa") improves the antitumour activity of tamoxifen ("Nolvadex") and ICI 182,780 ("Faslodex") in antihormone responsive breast cancer. Eur. J. Cancer, 38 (Suppl. 7): 59, 2002.
102. Gee, J. M. W., Harper, M. E., Hutcheson, I. R., Madden, T. A., Barrow, D., Knowlden, J. M., McClelland, R. A., Jordan, N., Wakeling, A. E., and Nicholson, R. I. The anti-EGFR agent gefitinib (ZD1839/Iressa™) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology, 144: 5105-5117, 2003.
103. Massarweh, S., Shou, J., Mohsin, S. K., Ge, M., Wakeling, A. E., Osborne, C. K., and Schiff, R. Inhibition of epidermal growth factor/HER2 receptor signalling using ZD1839 ("Iressa") restores tamoxifen sensitivity and delays resistance to oestrogen deprivation in HER2-overexpressing breast tumors. Proc. Am. Soc. Clin. Oncol., 21: 33, 2002.